癌症疫苗对晚期乳腺癌疗效的系统评价

IF 2.9
Breast cancer (Tokyo, Japan) Pub Date : 2025-09-01 Epub Date: 2025-08-05 DOI:10.1007/s12282-025-01751-1
Anna Charalampopoulou, Charalampos Filippatos, Panagiotis Malandrakis, Flora Zagouri, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos
{"title":"癌症疫苗对晚期乳腺癌疗效的系统评价","authors":"Anna Charalampopoulou, Charalampos Filippatos, Panagiotis Malandrakis, Flora Zagouri, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos","doi":"10.1007/s12282-025-01751-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cancer vaccines offer an innovative approach to treating advanced breast cancer, by activating the immune system to recognize and target cancer cells, aiming to boost immune response, reduce relapse, and enhance patients' quality of life.</p><p><strong>Methods: </strong>A systematic database search was conducted for peer-reviewed, full-text articles on clinical trials focused on cancer vaccines for advanced breast cancer, in the MEDLINE, SCOPUS, Cochrane and ClinicalTrials.gov databases, from conception until October 23, 2024.</p><p><strong>Results: </strong>A total of 19 trials, involving 747 patients with advanced breast cancer, were included in this systematic review. Cancer vaccine trials rely primarily on immunological endpoints, with initial small-scale studies showing modest efficacy improvements and highly variable immune response rates (44-100%), suggesting opportunities for further optimization and broader clinical application.</p><p><strong>Conclusion: </strong>While the overall quality of the studies was acceptable, heterogeneity in results and limited survival or progression outcomes prevented data synthesis. In conclusion, despite promising findings, the lack of large-scale randomized trials limits definitive conclusions on cancer vaccine efficacy, highlighting the need for Phase III trials to confirm their clinical utility and long-term impact.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"892-904"},"PeriodicalIF":2.9000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12394260/pdf/","citationCount":"0","resultStr":"{\"title\":\"A systematic review of the efficacy of cancer vaccines in advanced breast cancer.\",\"authors\":\"Anna Charalampopoulou, Charalampos Filippatos, Panagiotis Malandrakis, Flora Zagouri, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos\",\"doi\":\"10.1007/s12282-025-01751-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Cancer vaccines offer an innovative approach to treating advanced breast cancer, by activating the immune system to recognize and target cancer cells, aiming to boost immune response, reduce relapse, and enhance patients' quality of life.</p><p><strong>Methods: </strong>A systematic database search was conducted for peer-reviewed, full-text articles on clinical trials focused on cancer vaccines for advanced breast cancer, in the MEDLINE, SCOPUS, Cochrane and ClinicalTrials.gov databases, from conception until October 23, 2024.</p><p><strong>Results: </strong>A total of 19 trials, involving 747 patients with advanced breast cancer, were included in this systematic review. Cancer vaccine trials rely primarily on immunological endpoints, with initial small-scale studies showing modest efficacy improvements and highly variable immune response rates (44-100%), suggesting opportunities for further optimization and broader clinical application.</p><p><strong>Conclusion: </strong>While the overall quality of the studies was acceptable, heterogeneity in results and limited survival or progression outcomes prevented data synthesis. In conclusion, despite promising findings, the lack of large-scale randomized trials limits definitive conclusions on cancer vaccine efficacy, highlighting the need for Phase III trials to confirm their clinical utility and long-term impact.</p>\",\"PeriodicalId\":520574,\"journal\":{\"name\":\"Breast cancer (Tokyo, Japan)\",\"volume\":\" \",\"pages\":\"892-904\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12394260/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast cancer (Tokyo, Japan)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s12282-025-01751-1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/5 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast cancer (Tokyo, Japan)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12282-025-01751-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/5 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:癌症疫苗提供了一种治疗晚期乳腺癌的创新方法,通过激活免疫系统来识别和靶向癌细胞,旨在增强免疫反应,减少复发,提高患者的生活质量。方法:系统检索MEDLINE、SCOPUS、Cochrane和ClinicalTrials.gov数据库中关于晚期乳腺癌癌症疫苗临床试验的同行评审的全文文章,检索时间为从怀孕到2024年10月23日。结果:本系统综述共纳入19项试验,涉及747例晚期乳腺癌患者。癌症疫苗试验主要依赖于免疫学终点,最初的小规模研究显示出适度的疗效改善和高度可变的免疫应答率(44-100%),这表明有进一步优化和更广泛临床应用的机会。结论:虽然研究的总体质量是可以接受的,但结果的异质性和有限的生存或进展结果阻碍了数据的合成。总之,尽管有令人鼓舞的发现,但缺乏大规模随机试验限制了对癌症疫苗有效性的明确结论,强调需要进行III期试验以确认其临床效用和长期影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

A systematic review of the efficacy of cancer vaccines in advanced breast cancer.

A systematic review of the efficacy of cancer vaccines in advanced breast cancer.

Background: Cancer vaccines offer an innovative approach to treating advanced breast cancer, by activating the immune system to recognize and target cancer cells, aiming to boost immune response, reduce relapse, and enhance patients' quality of life.

Methods: A systematic database search was conducted for peer-reviewed, full-text articles on clinical trials focused on cancer vaccines for advanced breast cancer, in the MEDLINE, SCOPUS, Cochrane and ClinicalTrials.gov databases, from conception until October 23, 2024.

Results: A total of 19 trials, involving 747 patients with advanced breast cancer, were included in this systematic review. Cancer vaccine trials rely primarily on immunological endpoints, with initial small-scale studies showing modest efficacy improvements and highly variable immune response rates (44-100%), suggesting opportunities for further optimization and broader clinical application.

Conclusion: While the overall quality of the studies was acceptable, heterogeneity in results and limited survival or progression outcomes prevented data synthesis. In conclusion, despite promising findings, the lack of large-scale randomized trials limits definitive conclusions on cancer vaccine efficacy, highlighting the need for Phase III trials to confirm their clinical utility and long-term impact.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信